KALV News and Press, KalVista Pharmaceuticals Inc. From 02/22/23

Summary BioCryst's main value driver, ORLADEYO, is already profitable in its second year on the market and generated over $250 million in revenue in 2022. ORLADEYO is successfully differentiating itself in a multi-billion dollar market and is on track to achieve blockbuster status in a ...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 2023 Annual Scientific Meeting for the Ameri...

KalVista Pharmaceuticals ( NASDAQ: KALV ) reported clinical trial and regulatory updates for its lead drug sebetralstat, a potential oral on-demand therapy for hereditary angioedema (HAE) attacks. The company recently received additional FDA regulatory guidance for the oral disintegra...

- Phase 3 KONFIDENT clinical trial passes 50% enrollment milestone - - Topline data still expected in H2 2023 - KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, sma...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors today announced that results from the phase 2 trial evaluating the efficacy and safety of oral sebetral...

– Oral sebetralstat regimen for short-term prophylaxis to be evaluated in KONFIDENT-S – – Positive phase 1 sebetralstat data supports KONFIDENT trial expansion to Japan – KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it will be presenting at the SVB Securities Global Biopharma Conference (virtual) on Thu...

Summary KalVista intends to provide best-in-class therapies, both for acute on-demand and prophylaxis treatment, to fundamentally change the way HAE is treated. The backbone of the company is Sebetralstat, which is currently being investigated in a phase 3 trial for the on-demand treatm...

- Expanded role to lead business and commercial growth – - Follows $58 million financing in December 2022 led by top-tier syndicate – KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, ...

KalVista Pharmaceuticals ( NASDAQ: KALV ) is selling common shares and warrants to institutional investors in a registered direct offering to raise gross proceeds of ~$58M. The company is selling ~9.48M common shares at $6 per share and 182.47K prefunded warrants at $5.999 fo...